JP2005510246A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005510246A5 JP2005510246A5 JP2003547635A JP2003547635A JP2005510246A5 JP 2005510246 A5 JP2005510246 A5 JP 2005510246A5 JP 2003547635 A JP2003547635 A JP 2003547635A JP 2003547635 A JP2003547635 A JP 2003547635A JP 2005510246 A5 JP2005510246 A5 JP 2005510246A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- referred
- heavy chain
- antibody
- functional fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000008186 Collagen Human genes 0.000 claims description 39
- 108010035532 Collagen Proteins 0.000 claims description 39
- 229920001436 collagen Polymers 0.000 claims description 39
- 230000027455 binding Effects 0.000 claims description 21
- 150000001413 amino acids Chemical class 0.000 claims description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 9
- 238000006467 substitution reaction Methods 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims 242
- 239000008194 pharmaceutical composition Substances 0.000 claims 89
- 108090000765 processed proteins & peptides Proteins 0.000 claims 32
- 229920001184 polypeptide Polymers 0.000 claims 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims 29
- 230000001225 therapeutic effect Effects 0.000 claims 10
- 230000002401 inhibitory effect Effects 0.000 claims 6
- 230000002491 angiogenic effect Effects 0.000 claims 4
- 230000008685 targeting Effects 0.000 claims 4
- 210000005166 vasculature Anatomy 0.000 claims 4
- 206010027476 Metastases Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 6
- 230000035772 mutation Effects 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/995,529 US7365167B2 (en) | 2001-11-26 | 2001-11-26 | Humanized collagen antibodies and related methods |
| US10/011,250 US7390885B2 (en) | 2001-11-26 | 2001-12-06 | Humanized collagen antibodies and related methods |
| PCT/US2002/038147 WO2003046204A2 (en) | 2001-11-26 | 2002-11-26 | Humanized collagen antibodies and related methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009167279A Division JP2009240324A (ja) | 2001-11-26 | 2009-07-15 | ヒト化コラーゲン抗体および関連方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005510246A JP2005510246A (ja) | 2005-04-21 |
| JP2005510246A5 true JP2005510246A5 (https=) | 2006-01-12 |
| JP4519464B2 JP4519464B2 (ja) | 2010-08-04 |
Family
ID=26682164
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003547635A Expired - Fee Related JP4519464B2 (ja) | 2001-11-26 | 2002-11-26 | ヒト化コラーゲン抗体および関連方法 |
| JP2009167279A Withdrawn JP2009240324A (ja) | 2001-11-26 | 2009-07-15 | ヒト化コラーゲン抗体および関連方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009167279A Withdrawn JP2009240324A (ja) | 2001-11-26 | 2009-07-15 | ヒト化コラーゲン抗体および関連方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US7390885B2 (https=) |
| EP (1) | EP1478764B1 (https=) |
| JP (2) | JP4519464B2 (https=) |
| CN (1) | CN1596313B (https=) |
| AT (1) | ATE509955T1 (https=) |
| AU (1) | AU2009200070A1 (https=) |
| CA (1) | CA2468016A1 (https=) |
| IL (1) | IL162117A0 (https=) |
| MX (1) | MXPA04004857A (https=) |
| NZ (1) | NZ533408A (https=) |
| WO (1) | WO2003046204A2 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US7365167B2 (en) | 2001-11-26 | 2008-04-29 | Cell Matrix, Inc. | Humanized collagen antibodies and related methods |
| US7541440B2 (en) * | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
| AU2005214382B2 (en) | 2004-02-19 | 2011-08-04 | Genentech, Inc. | CDR-repaired antibodies |
| WO2007024921A2 (en) * | 2005-08-24 | 2007-03-01 | Cell Matrix | Combination therapies for inhibiting integrin-extracellular matrix interactions |
| AU2007258262A1 (en) * | 2006-06-14 | 2007-12-21 | Cell-Matrix, Inc. | Denatured collagen peptides and uses thereof |
| CN101484471B (zh) * | 2006-06-30 | 2013-11-06 | 诺沃-诺迪斯克有限公司 | 抗-nkg2a抗体及其用途 |
| KR20120017469A (ko) * | 2007-01-05 | 2012-02-28 | 유니버시티 오브 취리히 | 질환 특이적 결합 분자 및 표적을 제공하는 방법 |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| RS53174B (sr) | 2007-10-05 | 2014-06-30 | Genentech Inc. | Upotreba antiamiloidnog beta antitela u slučaju oboljenja oka |
| JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| US20110287036A1 (en) * | 2008-11-17 | 2011-11-24 | Riken | Novel cancer targeting therapy using complex of subtance capable of binding specifically to constituent factor of cancer stroma and anti-tumor compound |
| ES2529101T3 (es) * | 2009-03-30 | 2015-02-16 | Nordic Bioscience A/S | Ensayo de biomarcadores para fibrosis |
| WO2011049810A2 (en) | 2009-10-20 | 2011-04-28 | Maine Medical Center | Compositions and methods for treating inflammation and fibrosis |
| CN103068396B (zh) * | 2010-03-02 | 2016-07-06 | 诺沃姆德治疗公司 | 抑制c5和备解素相互作用的抗-备解素抗体在制备抑制交替途径活化的药剂中的用途 |
| RU2607368C2 (ru) | 2010-07-30 | 2017-01-10 | Ац Иммуне С.А. | Безопасные и функциональные гуманизированные антитела |
| WO2012063839A1 (ja) * | 2010-11-10 | 2012-05-18 | 日本化薬株式会社 | 抗１本鎖ｉｖ型コラーゲンポリペプチド抗体、並びに該抗体を含む医薬、及び腫瘍の診断薬、予防薬、又は治療薬 |
| BR112014006394A2 (pt) * | 2011-09-19 | 2017-03-28 | Kymab Ltd | manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos |
| US9777055B2 (en) | 2012-04-20 | 2017-10-03 | Thomas Jefferson University | Engineered antibody for inhibition of fibrosis |
| EP2904014A4 (en) | 2012-10-04 | 2016-09-28 | Novelmed Therapeutics Inc | FOR ALTERNATIVE PATHS, SPECIFIC ANTIBODIES FOR THE TREATMENT OF HEMOLYTIC DISEASES |
| CN105209493B (zh) | 2013-03-14 | 2019-05-03 | 德克萨斯州大学系统董事会 | 用于诊断和治疗用途的her3特异性单克隆抗体 |
| AU2017330346C1 (en) * | 2016-09-21 | 2025-03-06 | Nextcure, Inc. | Antibodies for Siglec-15 and methods of use thereof |
| EP3775258A4 (en) | 2018-03-28 | 2022-01-26 | Board of Regents, The University of Texas System | IDENTIFICATION OF EPIGENETIC ALTERATIONS IN DNA ISOLATED FROM EXOSOMES |
| WO2020081714A1 (en) * | 2018-10-16 | 2020-04-23 | Board Of Regents, The University Of Texas System | Identification and targeting of pathogenic extracellular matrix for diagnosis and treatment of cancer and other diseases |
| US12252538B2 (en) | 2018-11-16 | 2025-03-18 | Albert Einstein College Of Medicine | Monoclonal antibodies against IgV domain of B7-H3 and uses thereof |
| BR112021014420A2 (pt) * | 2019-01-28 | 2021-09-21 | Tuojie Biotech (Shanghai) Co., Ltd. | Anticorpo anti-cd79b, fragmento de ligação ao antígeno do mesmo e uso farmacêutico do mesmo |
| WO2021252974A2 (en) * | 2020-06-11 | 2021-12-16 | Proviva Therapeutics (Hong Kong) Limited | Collagen-targeted fusion proteins and antibodies |
| WO2022147298A1 (en) * | 2020-12-31 | 2022-07-07 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Vascular-endothelial cadherin activating antibodies and uses thereof |
| US20240358850A1 (en) * | 2023-04-13 | 2024-10-31 | MaineHealth | Compositions and methods for an antibody drug conjugate directed to a non-cell surface therapeutic target |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US91482A (en) * | 1869-06-15 | Improvement in harvesters | ||
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| ATE92499T1 (de) | 1984-12-04 | 1993-08-15 | Lilly Co Eli | Tumorbehandlung bei saeugetieren. |
| US5092885A (en) | 1987-02-12 | 1992-03-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Peptides with laminin activity |
| US5320970A (en) | 1987-11-06 | 1994-06-14 | Washington Research Foundation | Detection of collagen degradation in vivo |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6020145A (en) | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| US5192744A (en) | 1990-01-12 | 1993-03-09 | Northwestern University | Method of inhibiting angiogenesis of tumors |
| ATE130517T1 (de) | 1990-08-08 | 1995-12-15 | Takeda Chemical Industries Ltd | Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff. |
| US5264563A (en) | 1990-08-24 | 1993-11-23 | Ixsys Inc. | Process for synthesizing oligonucleotides with random codons |
| US5871974A (en) | 1990-09-28 | 1999-02-16 | Ixsys Inc. | Surface expression libraries of heteromeric receptors |
| JP3105629B2 (ja) | 1991-04-23 | 2000-11-06 | サングスタット メディカル コーポレイション | 特異的結合ペアのメンバーの細胞活性調節接合体 |
| DE69230545T2 (de) | 1991-08-21 | 2000-07-06 | Novartis Ag, Basel | Antikörperderivate |
| DE4127790A1 (de) | 1991-08-22 | 1993-02-25 | Wank Anna | Verwendung von oligopeptiden mit 2 bis 5 peptidbindungen fuer kosmetische zwecke und einige neue oligopeptid-metallkomplexe |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| JPH0675216A (ja) | 1992-08-27 | 1994-03-18 | Hitachi Ltd | 液晶表示装置 |
| CA2148132A1 (en) | 1992-12-04 | 1994-06-23 | Anthony Robin Poole | Immunoassay for the measurement of collagen cleavage in cartilage |
| US6132976A (en) | 1992-12-04 | 2000-10-17 | Shriners Hospitals For Children | Immunoassays for the measurement of collagen denaturation and cleavage in cartilage |
| US5541295A (en) | 1993-02-12 | 1996-07-30 | The Board Of Governors For Higher Education State Of Rhode Island And Providence Plantations | Detection of type II collagen and its peptides |
| JP2703116B2 (ja) | 1993-07-28 | 1998-01-26 | ベーリンガー マンハイム ゲーエムベーハー | コラーゲンまたはコラーゲン断片を検出するためのイムノアッセイ |
| US5510391A (en) | 1993-10-22 | 1996-04-23 | Mayapple Holdings, Llc | Method of treating blood vessel disorders of the skin using vitamin K |
| US5465826A (en) | 1994-02-24 | 1995-11-14 | Valiant Machine & Tool, Inc. | Conveyor system |
| US5560910A (en) | 1994-08-26 | 1996-10-01 | Crandall; Wilson T. | Topical anti-inflammatory composition and method |
| US5783184A (en) | 1994-12-23 | 1998-07-21 | Smithkline Beecham Corporation | Method for treatment and diagnosis of IL-5 mediated disorders |
| US5763272A (en) | 1994-12-23 | 1998-06-09 | Boehringer Mannheim Gmbh | Hybridoma for producing antibody for collagen I |
| US6001994A (en) | 1995-12-13 | 1999-12-14 | Eli Lilly And Company | Process for making gemcitabine hydrochloride |
| US5756775A (en) | 1995-12-13 | 1998-05-26 | Eli Lilly And Company | Process to make α,α-difluoro-β-hydroxyl thiol esters |
| AU2804297A (en) | 1996-04-22 | 1997-11-12 | Advanced Polymer Systems Inc. | Method of and composition for treating disorders of the skin using vitamin k |
| WO1997044059A2 (en) | 1996-05-23 | 1997-11-27 | Shriner's Hospitals For Children | Cartilage type ii collagen as an angiogenic factor |
| US6492508B1 (en) | 1996-06-03 | 2002-12-10 | United States Surgical Corp. A Division Of Tyco Healthcare Group | Nucleic acids encoding extracellular matrix proteins |
| US6590079B2 (en) | 1997-01-30 | 2003-07-08 | Ixsys, Incorporated | Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same |
| GB9702252D0 (en) | 1997-02-06 | 1997-03-26 | Univ Sheffield Medical The Sch | Collagen assay |
| US5817699A (en) | 1997-05-30 | 1998-10-06 | Flores; John A. | Process for the preparation of ketamine ointment |
| US5972623A (en) | 1997-07-31 | 1999-10-26 | Metra Biosystems, Inc. | Collagen-peptide assay method |
| AU8691398A (en) | 1997-08-04 | 1999-02-22 | Ixsys, Incorporated | Methods for identifying ligand specific binding molecules |
| AU5155198A (en) | 1997-08-28 | 1999-03-22 | Robert Murdock | Method and composition for transdermal administration of pharmacologic agent |
| US6030792A (en) | 1997-11-13 | 2000-02-29 | Pfizer Inc | Assays for measurement of protein fragments in biological media |
| WO2000023593A2 (en) | 1998-10-16 | 2000-04-27 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Molecular pathogenicide mediated plant disease resistance |
| US6833373B1 (en) * | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| ATE439369T1 (de) | 1999-01-06 | 2009-08-15 | Univ Southern California | Methode und zubereitung zur hemmung von angiogenese |
| US6521593B1 (en) | 1999-02-01 | 2003-02-18 | Childrens Hospital Los Angeles | Methods for inhibiting brain tumor growth |
| US6531580B1 (en) | 1999-06-24 | 2003-03-11 | Ixsys, Inc. | Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same |
| CN1379685A (zh) | 1999-07-13 | 2002-11-13 | 南加利福尼亚大学 | 用基于MMP－9和β1整联蛋白的拮抗剂抑制血管发生的新方法和组合物 |
| AU760486B2 (en) | 1999-10-13 | 2003-05-15 | Incyte Genomics, Inc. | Multiplex cytokine analysis |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| CA2399080C (en) | 2000-02-03 | 2013-05-21 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use therefor |
| AU2001243515A1 (en) | 2000-03-08 | 2001-09-17 | Rhode Island Hospital, A Lifespan Partner | Combination drug therapy |
| US6696254B2 (en) | 2001-11-21 | 2004-02-24 | Kimberly-Clark Worldwide, Inc. | Detection and identification of enteric bacteria |
| US7365167B2 (en) | 2001-11-26 | 2008-04-29 | Cell Matrix, Inc. | Humanized collagen antibodies and related methods |
| US20040241776A1 (en) | 2003-05-22 | 2004-12-02 | Agdia, Inc. | Multiplex enzyme-linked immunosorbent assay for detecting multiple analytes |
| JP2005347062A (ja) | 2004-06-02 | 2005-12-15 | Hitachi Displays Ltd | バックライト装置及び液晶表示装置 |
| JP2006075216A (ja) | 2004-09-07 | 2006-03-23 | Toshiba Corp | 医用画像処理システム、医用画像処理プログラムおよび医用画像処理方法 |
| AU2007258262A1 (en) | 2006-06-14 | 2007-12-21 | Cell-Matrix, Inc. | Denatured collagen peptides and uses thereof |
-
2001
- 2001-12-06 US US10/011,250 patent/US7390885B2/en not_active Expired - Fee Related
-
2002
- 2002-11-26 AT AT02795695T patent/ATE509955T1/de not_active IP Right Cessation
- 2002-11-26 NZ NZ533408A patent/NZ533408A/en not_active IP Right Cessation
- 2002-11-26 CN CN028264126A patent/CN1596313B/zh not_active Expired - Fee Related
- 2002-11-26 MX MXPA04004857A patent/MXPA04004857A/es not_active Application Discontinuation
- 2002-11-26 EP EP02795695A patent/EP1478764B1/en not_active Expired - Lifetime
- 2002-11-26 JP JP2003547635A patent/JP4519464B2/ja not_active Expired - Fee Related
- 2002-11-26 CA CA002468016A patent/CA2468016A1/en not_active Abandoned
- 2002-11-26 IL IL16211702A patent/IL162117A0/xx unknown
- 2002-11-26 WO PCT/US2002/038147 patent/WO2003046204A2/en not_active Ceased
-
2006
- 2006-07-14 US US11/486,894 patent/US7566770B2/en not_active Expired - Fee Related
-
2008
- 2008-05-08 US US12/117,642 patent/US7763248B2/en not_active Expired - Fee Related
-
2009
- 2009-01-08 AU AU2009200070A patent/AU2009200070A1/en not_active Abandoned
- 2009-07-15 JP JP2009167279A patent/JP2009240324A/ja not_active Withdrawn
-
2010
- 2010-06-10 US US12/813,352 patent/US20100303726A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005510246A5 (https=) | ||
| JP2025111463A5 (https=) | ||
| JP2022031635A5 (https=) | ||
| JP2011509245A5 (https=) | ||
| HRP20181069T1 (hr) | Antagonistička protutijela na il-17 | |
| ME02581B (me) | Farmaceutski pripravci s otpornošću na topljivi cea | |
| HRP20130922T1 (hr) | U potpunosti humana protutijela protiv humanog 4-1bb (cd137) | |
| JP2009225799A5 (https=) | ||
| JP2005503789A5 (https=) | ||
| JP2004527212A5 (https=) | ||
| JP2010502183A5 (https=) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2010533498A5 (https=) | ||
| JP2010536384A5 (https=) | ||
| JP2008532949A5 (https=) | ||
| JP2010511388A5 (https=) | ||
| JP2021521781A5 (https=) | ||
| WO2002072832A3 (en) | Therapeutic binding molecules | |
| JP2008538292A5 (https=) | ||
| JP2012500020A5 (https=) | ||
| JP2018537421A5 (https=) | ||
| JP2010524435A5 (https=) | ||
| JP2012532851A5 (https=) | ||
| WO2005026210A3 (en) | Therapeutic binding molecules | |
| JPWO2020059847A5 (https=) |